chloropyramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
606 59-32-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chloropyramine
  • chlorneoantergan
  • chloropyribenzamine
  • chlorpyramine
  • halopyramine
  • chloropyramine hydrochloride
  • chloropyramine HCl
  • Molecular weight: 289.81
  • Formula: C16H20ClN3
  • CLOGP: 4.02
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 19.37
  • ALOGS: -2.82
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.15 g O
20 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.317 Moderate 0.71
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.380 Moderate 0.71
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 38.815 10^-6 cm/s Moderate 0.71
dh-clint Dog hepatocyte intrinsic clearance 110.917 uL/min/10^6 cells Moderate 0.71
dppb Dog plasma protein binding (% unbound) 25.970 % Moderate 0.71
fcs-ppb Fetal calf serum protein binding (% unbound) 36.740 % Moderate 0.71
herg hERG pIC50 6.013 pIC50 Moderate 0.71
hh-clint Human hepatocyte intrinsic clearance 15.631 uL/min/10^6 cells Moderate 0.71
hlm-clint Human liver microsomal intrinsic clearance 40.926 uL/min/mg protein Moderate 0.71
hppb Human plasma protein binding (% unbound) 25.010 % Moderate 0.71
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K7,MAPK10,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK 37
kinase-selectivity-class AXL,BRAF,EIF2AK3,ERBB2 4
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.270 Moderate 0.71
mh-clint Mouse hepatocyte intrinsic clearance 181.970 Moderate 0.71
mppb Mouse plasma protein binding (% unbound) 26.230 Moderate 0.71
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.021 Moderate 0.71
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 47.760 % Moderate 0.71
rh-clint Rat hepatocyte intrinsic clearance 191.867 uL/min/10^6 cells Moderate 0.71
rh-fuinc Rat hepatocyte fraction unbound in incubation 52.470 % Moderate 0.71
rppb Rat plasma protein binding (% unbound) 30.290 % Moderate 0.71
solubility-dd Solubility at pH 7.4 in DMSO 944.061 uM Moderate 0.71

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaccination site reaction 73.59 45.57 10 821 247 90627369
Pleural neoplasm 68.43 45.57 10 821 421 90627195
Cranial nerve disorder 48.99 45.57 8 823 699 90626917
Carcinoembryonic antigen 46.86 45.57 6 825 92 90627524
Carbohydrate antigen 15-3 46.51 45.57 6 825 98 90627518

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vaccination site reaction 73.67 37.86 10 1036 237 110588016
Pleural neoplasm 68.51 37.86 10 1036 404 110587849
Carcinoembryonic antigen 46.67 37.86 6 1040 92 110588161
Carbohydrate antigen 15-3 46.20 37.86 6 1040 100 110588153
Breast disorder 45.23 37.86 9 1037 2305 110585948
Cranial nerve disorder 43.89 37.86 8 1038 1289 110586964
Bacteriuria 43.06 37.86 8 1038 1430 110586823
Body temperature increased 39.53 37.86 16 1030 54697 110533556
Right ventricular dilatation 39.02 37.86 8 1038 2379 110585874

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D04AA09 DERMATOLOGICALS
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
Antihistamines for topical use
ATC R06AC03 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Substituted ethylene diamines
ATC R06AC53 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Substituted ethylene diamines
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018494 Histamine Agents

Related Drugs by ATC class:

D04AA Antihistamines for topical use 13 drugs
bamipinechlorphenoxamineclemastinedimetindenediphenhydramineisothipendylmepyraminepheniraminepromethazinethenalidinethonzylaminetolpropamine show all 13 →
R06AC Substituted ethylene diamines 5 drugs
histapyrrodinemepyraminemethapyrilenethonzylaminetripelennamine

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.62 Basic
pKa2 4.33 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Focal adhesion kinase 1 Kinase Kd 6.24 CHEMBL

External reference:

IDSource
D07195 KEGG_DRUG
20861 RXNORM
C0055445 UMLSCUI
CHEBI:94767 CHEBI
C4C PDB_CHEM_ID
CHEMBL1194287 ChEMBL_ID
DB08800 DRUGBANK_ID
C004664 MESH_SUPPLEMENTAL_RECORD_UI
25295 PUBCHEM_CID
179 INN_ID
6170-42-9 SECONDARY_CAS_RN
2K3L8O9SOV UNII
005999 NDDF
006000 NDDF
2K3L8O9SOV INXIGHT DRUGS

Pharmaceutical products:

None